Role of Diet on the Microbiome of the Digestive System

Sponsor
M.D. Anderson Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04666727
Collaborator
(none)
20
1
15.1
1.3

Study Details

Study Description

Brief Summary

This study is to learn more about how diet affects the microbiome (bacteria and microorganisms) of the digestive system. Researchers want to learn if this, in turn, has an effect on if and how people then develop colorectal cancer.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    PRIMARY OBJECTIVES:
    1. To evaluate the differences in dietary patterns among individuals reporting to be vegetarian and omnivorous.

    2. To compare the difference in stool microbiome pattern in the above mentioned two groups of individuals.

    3. To compare somatic mutations in colorectal epithelial cells in the above mentioned two groups of individuals.

    SECONDARY OBJECTIVE:
    1. To identify and characterize an association between diet, the microbiome and its genotoxic effect on the colorectal epithelial cells and predisposition to colorectal carcinogenesis.
    OUTLINE:

    Participants complete dietary questionnaire over 30-60 minutes and undergo collection of stool, blood, and tissue samples for analysis via sequencing and laser dissection.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    20 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Role of Diet and the Microbiome in Inducing Somatic Mutations in Colorectal Epithelial Cells and Its Predisposition to Carcinogenesis - A Pilot Study
    Actual Study Start Date :
    Sep 29, 2020
    Anticipated Primary Completion Date :
    Jan 1, 2022
    Anticipated Study Completion Date :
    Jan 1, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Dietary patterns [Baseline]

      Will obtain estimates of dietary patterns from colonic mucosal biopsies in each group.

    2. Microbiome composition [Baseline]

      Will obtain estimates of microbiome composition from colonic mucosal biopsies in each group. Microbiome composition will be quantified using 16S profiling will be visualized across samples using stacked bar plots and principal coordinate analysis of the weighted Unifrac distances, and microbiome diversity within each sample will be quantified using the inverse-Simpson index.

    3. Somatic mutation burden [Baseline]

      Will obtain estimates of somatic mutation burden from colonic mucosal biopsies in each group.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • GROUP I: Patients presenting for a screening colonoscopy

    • GROUP I: Age of 50 and above

    • GROUP I: Strict vegetarian diet, determined by using diet history questionnaire 3.0 National Institutes of Health (NIH)

    • GROUP I: Non smoker

    • GROUP I: Ability to understand and willingness to sign an informed consent form, complete web based dietary assessment and provide stool, colonic mucosa and blood samples

    • GROUP II: Patients presenting for a screening colonoscopy

    • GROUP II: Age of 50 and above

    • GROUP II: Omnivorous diet

    • GROUP II: Non smoker

    • GROUP II: Ability to understand and willingness to sign an informed consent form, complete web based dietary assessment and provide stool, colonic mucosa and blood samples

    Exclusion Criteria:
    • • Current smokers (nicotine abuse only)

    • Positive family history of colon cancer or colon cancer related syndromes

    • Recent use of antibiotics in 1 month

    • History of inflammatory bowel disease, and/or radiation enteritis or colitis

    • Pregnant and breastfeeding women

    • Women of child-bearing potential who have positive urine or serum pregnancy test

    • Heavy drinker (defined as more than 14 drinks per week)

    • Currently using anti-flatulence medications, probiotics and/or fiber supplements

    • Major dietary restrictions and/or following a special diet

    • Patient with positive fecal test/symptoms

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 M D Anderson Cancer Center Houston Texas United States 77090

    Sponsors and Collaborators

    • M.D. Anderson Cancer Center

    Investigators

    • Principal Investigator: Anusha Thomas, MD, MD Anderson Cancer Center, Houston, Texas

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    M.D. Anderson Cancer Center
    ClinicalTrials.gov Identifier:
    NCT04666727
    Other Study ID Numbers:
    • 2019-1148
    First Posted:
    Dec 14, 2020
    Last Update Posted:
    Nov 22, 2021
    Last Verified:
    Nov 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 22, 2021